

JAN. 4. 2005 2:51PM

AVENTIS US PAT DEPT

NO. 1077 P. 6

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (10-85)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/035,783		
		Filing Date	12/24/2001		
		First Named Inventor	GRAUPE		
		Group Art Unit	1626		
		Examiner Name	Shaio		
Sheet	1	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
[Signature]		4,927,809		STUBER, et al.	05-22-1990	
		5,424,325		ANDO, et al.	08-19-1995	
		5,486,623		ZIMMERMAN, et al.	01-23-1996	
		5,498,816		MALLANO, et al.	03-12-1996	
		5,847,135		BEMIS, et al.	12-08-1998	
		6,852,007		CHATTERJEE, et al.	12-22-1998	
		5,874,424		BATCHELOR, et al.	02-23-1999	
		5,998,390		RAMAMURTHY, et al.	12-07-1999	
		6,004,939		SPRUCE, et al.	12-21-1999	
		6,022,661		SCARBOROUGH, et al.	02-08-2000	
[Signature]		6,114,310		CHAMBERLAND, et al.	09-05-2000	
		6,124,333		MILLER, et al.	12-26-2000	
		6,255,453		GYORKOS	07-03-2001	
		6,353,017		ALTMAN, et al.	03-05-2002	
		6,455,502		BRYANT, et al.	09-24-2002	
		6,476,026		BRYANT, et al.	11-05-2002	
		6,492,382		GRAUPE, et al.	12-10-2002	
		6,608,733		BUYASSE	01-14-2003	
		6,576,830		LINK, et al.	06-10-2003	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ⁴	Number ⁴	Kind Code ² (if known)				
A		EP	EP 0272671		KRANTZ, et al.	06-29-1988		
		EP	EP 0291234		EDWARDS, et al.	11-17-1998		
		EP	EP 0355572		PAQUES, et al.	02-28-1990		
		EP	EP 0376012		ALBRIGHT, et al.	07-04-1990		
		EP	EP 0418883		HARA, et al.	04-03-1991		
		EP	EP 0536399		OKUBO, et al.	04-01-1993		
		EP	EP 0652009		DOVEY, et al.	10-05-1995		
		EP	EP 0754454		KOBAYASHI, et al.	01-22-1997		
		JP	JP 08192199		RYOICHI, et al.	07-12-1994		
		JP	JP 42009133		IRIKURA, et al.	05-08-1987		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEE\$ OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

AVENTIS US PAT DEPT

NO. 1077 P. 7

Please type a plus sign (+) inside this box →

PTOVSEB/DBA (10-86)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete If Known Application Number 10/035,783 Filing Date 12/24/2001 First Named Inventor GRAUPE Group Art Unit 1826 Examiner Name Shalo Attorney Docket Number USAV2001/0081 - US - NP	
Sheet	2	of	13		

[illegible]

FOREIGN PATENT DOCUMENTS							
Examiner (Initials)	Oite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TS
		Office ²	Number ⁴				
/		JP	JP 63303888		YOSHIDA, et al.	12-08-1983	
		WO	WO 00/48992		TUCKER, et al.	08-24-2000	
		WO	WO 00/49007		TUCKER, et al.	08-24-2000	
		WO	WO 00/49008		TUCKER, et al.	08-24-2000	
		WO	WO 00/51996		CYWIN, et al.	09-08-2000	
		WO	WO 00/59881		SINGH, et al.	10-12-2000	
		WO	WO 00/68856		QUIBELL, et al.	11-23-2000	
		WO	WO 01/09110		BEKKALI, et al.	02-08-2001	
		WO	WO 01/18798		GRAUPE, et al.	09-22-2001	
		WO	WO 01/19808		GRAUPE	03-22-2001	

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>5/1/05</i>
-----------------------	--------------------	--------------------	---------------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

AVENTIS US PAT DEPT

NO. 1077 P. 8

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-96)

Approved for use through 10/31/98. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known Application Number 10/035,783 Filing Date 12/24/2001 First Named Inventor GRAUPE Group Art Unit 1626 Examiner Name Shaio Attorney Docket Number USAV2001/0081 - US - NP	
Sheet	3	of	13		

[illegible]

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.1	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Page, Column, Line, Where Relevant Passages or Relevant Figures Appear	TV
		Office ³	Number ⁴				
✓		WO	WO 01/19816		EMMANUEL, et al.	03-22-2001	
		WO	WO 01/30772		TUCKER, et al.	05-03-2001	
		WO	WO 01/65125		BOZSING, et al.	08-02-2001	
		WO	WO 01/68886		MISSBACH, M.	08-16-2001	
		WO	WO 95/12089		MORRIELLO, et al.	05-18-1995	
		WO	WO 95/15309		JENKINS, et al.	06-08-1995	
		WO	WO 95/24382		HALLINAN, et al.	08-14-1995	
		WO	WO 98/21655		PEET, et al.	07-18-1998	
		WO	WO 98/30353		PALMER, et al.	10-03-1998	
		WO	WO 96/40847		ZIMMERMAN, et al.	12-19-1996	

Examiner Signature	<i>[Signature]</i>	Date Considered	5/7/05
-----------------------	--------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

NO. 1077 P. 9

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-99)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/035,783	
			Filing Date	12/24/2001	
			First Named Inventor	GRAUPE	
			Group Art Unit	1828	
			Examiner Name	Shale	
Sheet	4	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

[illegible]

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TS
		Office ³	Number ⁴				
W		WO	WO 86/40744		MARLOWE, et al.	12-18-1986	
		WO	WO 88/41638		DOLLE, et al.	12-27-1988	
		WO	WO 87/03679		MALLANO, et al.	02-08-1987	
		WO	WO 88/01133		AIBE, et al.	01-15-1988	
		WO	WO 88/01428		DOMINGUEZ, et al.	01-15-1988	
		WO	WO 88/05336		MARQUIS, et al.	02-12-1988	
		WO	WO 88/08802		YAMASHITA, et al.	03-05-1988	
		WO	WO 88/08867		SHIONOGI, et al.	03-05-1988	
		WO	WO 88/21188		PRESTON, et al.	06-22-1988	
		WO	WO 88/23588		FLOYD, C.	08-04-1988	

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>6/27/05</i>
-----------------------	--------------------	--------------------	----------------

***EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

NO. 1077 P. 10

PTO/5B/D8A (10-85)

Approved for use through 10/31/99. OMB 0831-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/035,783
				Filing Date	12/24/2001
				First Named Inventor	GRAUPE
				Group Art Unit	1628
				Examiner Name	Shaio
Sheet	5	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	---	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 19 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/09. CMB 0561-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/035,783	
			Filing Date	12/24/2001	
			First Named Inventor	GRAUPE	
			Group Art Unit	1626	
			Examiner Name	Shiao	
Sheet	6	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issu number(s), publisher, city and/or country where published.
		ADAMS, et al., Potent and Selective Inhibitors of the Proteasome: Dipeptidyl Boronic Acids, Bioorganic & Medicinal Chemistry Letters, 8: 333-338 (1998).
		ASHWORTH, et al., 4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV, Bioorganic & Med. Chem. Letters, 8, Oxford, 6(22):2745-2748 (1996).
		BERGEMAN, et al., Studies on the reactivity of .alpha.-cyano.alpha.-isocyano alkanoates. Versatile synthons for the assembly of imidazoles, Helv. Chim. ACTA, 82(6):909-918 (1999).
		BILLSON, et al., The Design and Synthesis of Inhibitors of the Cysteine, Bioorg. Med. Chem. Lett. vol. 8, pp. 993-998, 1998
		BROMME, et al., Potent Inactivation of Cathepsins S and L, Biol. Chem. Hoppe-Seyler. vol. 375, No. 5, pp. 343-347, 1994.
		CHATTERJEE, et al., D-Amino Acid Containing, High-Affinity Inhibitors of Recombinant Human Calpain I, Journal of Medicinal Chemistry, vol. 41, No. 15, p: 2663-2665 (1998).
		COHEN, et al., Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders, Journal of Neuroimmunology, 98: 29-36 (1999).
		DUFOR, et al., Engineering nitrile hydratase activity into a cysteine protease by a single mutation, Biochemistry, US, Am. Chem. Soc., Easton, PA, 34(50):16382-16388 (1995).
		EDWARDS, et al., Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl a-Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Purine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole, Journal of American Chemical Society, vol. 114, No. 5, p 1854-1863 (1992).
		EVOLI, et al., abstract only, Drugs, 1998, 52(6), 662-70

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-95)

Approved for use through 10/31/99, OMB 0881-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
			Application Number	10/035,783	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Filing Date	12/24/2001	
			First Named Inventor	GRAUPE	
			Group Art Unit	1626	
			Examiner Name	Shalo	
Sheet	7	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GOUR-SALIN, et al., Inhibition of papain by peptide nitriles: conversion of the nitrile group into other functionalities via the papain-nitrile thiomidate ester adduct, Can. J. of Chem, CA, National Research Council, Ottawa, 69(8):1268-1297 (1991).	
		HALLEGUA, et al., Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, Lupus, 9: 241-251 (2000).	
		HANZLIK, et al., Reversible covalent binding of peptide nitriles to papain, Biochim. Biophys. Acta, vol. 1035, No. 1, 1990, pp. 62-70.	
		HARRIS, et al., Characteristics of a continuous fluorogenic assay for calpain I. Kinetic evaluation of peptide aldehydes, halomethyl ketones and (achalasia) methyl ketones as inhibitors of the enzyme, Chemical Abstracts, 110:7, Bioorg. Med. Chem. Lett, 5(4) 393-398 (1995).	
		HEITMILLER, R.F., abstract only, Semin. Thorac. Cardiovasc. Surg., 1999, 11(1), 41-6	
		KATRITZKY, et al., Benzotriazole-assisted synthesis of alpha-(acylamino) nitriles and a conceptually novel method for peptide elongation, Chem. Soc., Perkin Trans. 1(7):1853-1857 (1990).	
		KHAMASHTA, et al., Expert. Opin. Investig. Drugs, 2000, 6(7), 1581-83.	
		KRANTZ, et al., Peptidyl (Acloxy)methyl Ketones and the Quiescent, Biochemistry, vol. 30, pp. 4678-4687, 1991	
		LEVY, E.G., Baillieres Clin. Endocrinol. Metab., 1997, 11(3) 585-695	
		LI, et al., Aminoacylpyrrolidine-3-nitriles: Potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26), Archives of Biochem. and Bioph., 323(1)148-154 (1995).	

Examiner Signature		Date Considered	1/4/05
--------------------	--	-----------------	--------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burdur Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/089 (10-88)
Approved for use through 10/31/89. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/035,783		
		Filing Date	12/24/2001		
		First Named Inventor	GRAUPE		
		Group Art Unit	1626		
		Examiner Name	Shiao		
Sheet	8	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LIPSHUTZ, et al., Chiral induction in originally racemic amino acids via 5-acyl and 5-acyloxyaminooxazoles, <i>Isr. J. Chem.</i> 27(1):49-55 (1986), abstract.	
		LIPSHUTZ, et al., Heterocycles as masked diamide/dipeptide equivalents. Formation and reactions of substituted 5-(acylamino)oxazoles as intermediates en route to the cyclopeptide alkaloids, <i>Am. Chem. Soc.</i> , 105(28):7703-7713 (1983).	
		LIPSHUTZ, et al., Oxazolophanes as masked cyclopeptide alkaloid equivalents: cyclic peptide chemistry without peptide couplings, <i>J. Am. Chem. Soc.</i> , 112(18):7032-7041 (1990).	
		MARQUIS, et al., Potent dipeptidylketone inhibitors of the cysteine protease cathepsin, <i>Chemical Abstracts</i> , 7:4 681-588 (1999).	
		MCMATH, et al., Direct dialkylation of peptide nitriles. Application of the synthesis of 1-aminocyclopropane-1 carboxylic acid (Aoc)-containing dipeptides, <i>Bull. Soc. Chim. Fr.</i> 134(1):105-110 (1987).	
		MORIYA, et al., Synthesis and Hypolipidemic Activities of 5-Thienyl-4-oxazoleacetic Acid Derivatives, <i>sup.1, J. Med. Chem.</i> , 29: 333-341 (1986).	
		MOSE, et al., 130 Poly (dipeptamidinium)-Salze: definition und metoden zur preparativen herstellung, poly (dipeptamidinium) salts: definition and methods of preparation, <i>Helvetica Chimica ACTA, CH, Verlag, Basel</i> 69:1224-1262 (1986).	
		NIPPON, K., Patent Abstracts of Japan, Publication No. 63301868, 013(137)(1988), abstract.	
		NORTH, et al., Synthetic studies towards cyclic peptides. Concise synthesis of thiazoline and thiazole containing amino acids, <i>Tetrahedron</i> , 48(24):8627-8290 (1990).	
		OGILVIE, et al., Peptidomimetic inhibitors of the human cytomegalovirus protease, <i>Journal of Medicinal Chemistry</i> vol. 40 No. 25 (1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐PTO/SB/088 (10-98)
Approved for use through 10/31/98. OMB 0561-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/035,763	
			Filing Date	12/24/2001	
			First Named Inventor	GRAUPE	
			Group Art Unit	1626	
			Examiner Name	Shalo	
Sheet	9	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
		PICKEN, et al., Inhibition of bovine cathepsin B by amino acid-derived nitriles, Biochemical Society Transactions, vol. 18, No. 2, p:316 (1990).	
		PLIURA, et al., Comparative behavior of colpain and cathepsin B, Biochem. J. vol. 288, pp. 759-762, 1992	
		POLMAN, et al., Drug treatment of multiple sclerosis, BMJ, 321: 19-26 (2000).	
		RIESE, et al., Essential Role for Cathesin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading, Immunity, 4: 357-368 (Apr. 1996).	
		SMITH, et al., New Inhibitors of Cysteine Proteinases, J. Am. Chem. Soc. vol. 110, No. 13, pp. 4429-4431, 1988	
		SUAVE, et al., Carboxylmodified amino acids and peptides, I An efficient method for the synthesis of monofunctionalized enamines and monofunctionalized methyl ketone derivatives from thioamides via epoxide and thioiminium salts, Tetrahedron Lett, 29:19 2295-2298 (1988).	
		SUZUE, S., Hepatic agents. I. Synthesis of aminocyl (and hydroxycyl) aminoacetone nitriles, Chem. and Pharm. Bull. (Tokyo) (1968), 16(8), 1417-32.	
		SUZUE, et al., Studies on Heptic Agents, Chem. Pharm. Bull. vol. 16, No. 8, pp. 1417-1432, Aug. 1968.	
		SUZUKI, et al., Synthesis of 2-Aryl-4-(3-thienyl)imidazole Derivatives with Antiinflammatory Properties .sup.1), Chem. Pharm. Bull. 34(8): 3111-3120 (1988).	
		TAO, et al., Inhibition of Calpain By Peptidyl Heterocycles, Bioorganic & Medicinal Chemistry Letters, 6:24 3009-3112 (1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/99. CMB 0631-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/035,783	
			Filing Date	12/24/2001	
			First Named Inventor	GRAUPE	
			Group Art Unit	1628	
			Examiner Name	Shalo	
Sheet	10	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		THOMPSON, et al., Carboxyl-modified amino acids and peptides as protease inhibitors, J. Med. Chem., 29(1):104-111 (1986).	
		TSUTSUMI, et al., Synthesis and Structure-Activity Relationships of Peptidyl a-Keto Heterocycles as Novel Inhibitors of Prolyl Endopeptidase, Journal of Medicinal Chemistry, vol. 37, No. 21, p 3482-3502 (1994).	
		VARGHA, E., Peptide derivatives. VI. N-protected di- and tripeptide nitriles, Stud. Univ. Babeş-Bolyai, Ser. Chem., 19(2):31-5 (English abstract of article in Romanian) (1966).	
		VARGHESE, The structure and resonance Raman spectra-structure correlations for methoxycarbonyl-L-phenylalanyl-L-alanine ethyl dithioester, Can. J. Chem., 64(8):1668-1673 (1986).	
		YAMADA, et al., Studies of unusual amino acids and their peptides. IX. The synthetic study of bomamycin B1 and B2, Bul. Chem. Soc., Jpn. 51(3):878-83 (1978), abstract.	
		, Derwent Abstract of Japanese Patent Application 08-182199, (Jul. 12, 1994).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/99, CMB 0651-0031
 Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 13

Complete if Known

Application Number 10/035,783
 Filing Date 12/24/2001
 First Named Inventor GRAUPE
 Group Art Unit 1826
 Examiner Name Shaio
 Attorney Docket Number USAV2001/0081 - US - NP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Paragraphs or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		09/927,188		CAI, et al.	08-10-2001	
		09/927,324		BUTLER, et al.	08-10-2001	
		09/928,122		BREITENBUCHER, et al.	08-10-2001	
		09/946,214		GU, et al.	08-05-2001	
		10/042,565		QUIBELL, et al.	11-18-2001	
		10/148,612		OHMOTO, et al.	08-21-2002	
		10/148,613		OHMOTO, et al.	08-28-2002	
		10/181,713		OHMOTO, et al.	07-22-2002	
		10/181,789		OHMOTO, et al.	07-23-2002	
		10/231,425		BUXTON, et al.	08-28-2002	
		10/256,512		BEKKALI, et al.	08-27-2002	
		10/258,053		CUMMINGS, et al.	10-17-2002	
		10/275,583		COWEN, et al.	11-07-2002	
		10/279,424		BEKKALI, et al.	10-24-2002	
		10/488,385		QUIBELL, et al.	01-08-2004	
		6,015,791		GYORKOS, et al.	01-18-2000	
		6,608,057		CYWIN, et al.	08-18-2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Paragraphs or Relevant Figures Appear	T ³
		Office ³	Number ⁴	Kind Code ² (if known)				
		JP	JP 2001-011037		SATO, et al.	01-18-2001		
		JP	JP 2001-055366		SATO, et al.	02-27-2001		
		WO	WO00/59881		SINGH, et al.	10-12-2000		
		WO	WO01/09169		SINGH, et al.	02-08-2001		
		WO	WO02/057248		QUIBELL, et al.	07-25-2002		
		WO	WO02/057249		QUIBELL, M	07-25-2002		
		WO	WO02/057270		QUIBELL, M	07-25-2002		
		WO	WO02/086892		OHMOTO, et al.	05-30-2002		
		WO	WO02/100849		HICKEY, et al.	12-19-2002		
		WO	WO02/20485		BEKKALI, et al.	03-14-2002		

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/99. OMB 0691-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/035,783	
			Filing Date	12/24/2001	
			First Named Inventor	GRAUPE	
			Group Art Unit	1628	
			Examiner Name	Shalo	
Sheet	12	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published.	T ²
MB		CHAPMAN, et al., Emerging Roles for Cysteine Proteases in Human Biology, Ann. Rev. Physiol.; 1997; 59; pp.63-88.	
		DRANOFF, et al., Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development, Immunity; 1999; 10; pp.197-208.	
		FENWICK, et al., Diastereoselective Synthesis, Activity and Chiral Stability of Cyclic Alkoxyketone Inhibitors of Cathepsin K, Bioorg. Med. Chemm. Lett.; 2001; 11(2); pp.199-202.	
		FENWICK, et al., Solid-phase Synthesis of Cyclic Alkoxyketones, Inhibitors of the Cysteine Protease Cathepsin K, Bioorg. Med. Chem. Lett.; 2001; 11(2); pp.195-198.	
		GREENSPAN, et al., Identification of Dipeptidyl Nitriles as Potent and Selective Inhibitors of cathepsin B Through Structure-based Drug Design, J. Med. Chem.; 2001; 44; pp.4524-4534.	
		LOWE, et al., Kinetic Specificity in Papain-catalyzed Hydrolyses, Biochem. J.; 1971; 124(1); pp.107-115.	
		MACIEWICZ, et al., A comparison of Four Cathepsins (B, L, N and S) with Collagenolytic Activity From Rabbit Spleen, Biochem J.; 1998; 256; pp.433-440.	
		MARQUIS, et al., Azetione-based Inhibitors of Human and Rat Cathepsin K, J. Med. Chem.; 2000; 44(9); pp.1380-1385.	
		NAKAGAWA, et al., Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-induced Arthritis in Cathepsin S-null Mice, Immunity; 1999; 10; pp.207-217.	
MB		OTTO, et al., Cysteine Proteases and their Inhibitors, Chem. Rev.; 1997; 97; pp.133-171.	

Examiner Signature		Date Considered	1/4/05
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/035,783		
		Filing Date	12/24/2001		
		First Named Inventor	GRAUPE		
		Group Art Unit	1826		
		Examiner Name	Shalo		
Sheet	13	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
JS		SHI, et al., Molecular Cloning and Expression of Human Alveolar Macrophage Cathepsin B, an Elastolytic Cysteine Protease, J. Biol. Chem., 1992; 267; pp.7258-7262.	
JS		SINGH, et al., beta-lactams as Enzyme Inhibitors., IDrugs; 2000; 3(6); pp.612-617.	
JS		VILLADANGOS, et al., Cathepsin B Activity Regulates Antigen Presentation and Immunity, J. Clin. Invest.; 1998; 101(10); pp.2351-2363.	

Examiner Signature		Date Considered	1/4/05
-----------------------	--	--------------------	--------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.